GFAP and anti-neutrophil cytoplasmic antibody-associated vasculitis: Nevertheless, as a pilot study, the findings are clinically significant, and a prospective study with more patients and kidney biopsy data is needed to validate these results and provide a more comprehensive understanding of GFAP’s clinical utility in AAV.